Optimizing Biomarker-Directed Therapy to Advance CRC Care: A Clinical Connections Session (Enduring from 72WC231)

Intended Audience: Medical and surgical oncologists in community and academic settings and their clinical teams of NPs, PAs, nurses, and pharmacists, as well as pathologists.

Novel and emerging biomarkers are improving outcomes for patients with colorectal cancer (CRC). Tune in for a comprehensive discussion on the latest advances in biomarker-directed therapy for CRC.

During this Clinical Connections webcast, multidisciplinary oncology experts discuss:

• Incorporating biomarker testing into treatment selection and sequencing
• The latest clinical efficacy and safety data of biomarker-driven combination therapies
• Coordinating multidisciplinary care

Be sure to download the Biomarker Testing Resource available as part of this program!

• Describe the established biomarkers and recommended biomarker tests for patients with colorectal cancer
• Evaluate evolving clinical data on the efficacy, safety, and utility of novel biomarker-driven combination therapies for the treatment of unresectable or metastatic colorectal cancer
• Apply biomarker testing results to guide treatment selection for patients with unresectable or metastatic colorectal cancer
• Assess potential logistical considerations for the incorporation of comprehensive colorectal cancer biomarker testing into clinical practice

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.0 contact hour (which includes 0.56 hour of pharmacology).

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• Nikoletta Sidiropoulos, MD (Speaker)
  
  Advisory Board or Panel – Bayer, Genentech, Merck, PierianDx
  Consultant – Bayer, Genentech, PierianDx
  The relationships reported above are related to the following therapeutic area: Oncology
• Sameh Mikhail, MD (Speaker)
  
  Advisory Board or Panel – Ipsen
  Consultant – Ipsen
  Speakers Bureau or other Promotional Education – Ipsen
  The relationships reported above are related to the following therapeutic area: Solid Tumor

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Antonia Sepulveda, MD (Speaker)
• Abimbola Farinde, PhD, PharmD (Reviewer)
• Richa Bhattarai, MD (Planner)
• Lisa Wakefield, MSN, APRN, FNP-BC (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.